When we learn something new, at that time a channel opens inside the brain cell and not close, which will result in a flood of calcium, Kittur said.
These are better than not taking anything, she said and will be continued during the trial.
The current medications are mostly aimed at maximizing the brain activity; The ICARA study is evaluating the safety and effectiveness of a new drug aimed at slowing down the disease progression and possibly even helping with prevention.
The conditions of the trial include:
A caregiver must be present at all treatments.
Participant between the ages of 50 and 88.
Must pass a test that determines presence of AD.
Damage to the brain, such as a stroke or an aneurysm C will disqualify the patient.
Other significant neurological disease or major psychiatric disorder will disqualify the patient.
Persons interested in the study will remain on their current AD medications throughout.
There is a 60-percent chance of receiving the drug and a 40-percent chance of receiving a placebo.
A woman can not be of childbearing potential
How can participants benefit?
Clinical research is necessary to determine whether this new drug works and if it is safe. There is no guarantee, but the information gathered from this study could help future AD patients.
Participants will receive the investigational drug, physical exams, as well as laboratory services and tests. Throughout the study, participants will be monitored by a medical team including a nurse (or study coordinator) and a physician.
What the trial will entail?
There will be no charge to participate.
The procedure is a 45 minutes infusion, for a total of six times with 13 weeks in between each infusion.
There is also a four-hour monitoring of the patient immediately following the first infusion and then two-hour monitoring at the subsequent five infusions.